| Diabesity: an overview of a rising epidemic YMK Farag, MR Gaballa Nephrology Dialysis Transplantation 26 (1), 28-35, 2011 | 453 | 2011 |
| Management of myeloma-associated renal dysfunction in the era of novel therapies MR Gaballa, JP Laubach, RL Schlossman, K Redman, K Noonan, ... Expert review of hematology 5 (1), 51-68, 2012 | 55 | 2012 |
| Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia MR Gaballa, P Banerjee, DR Milton, X Jiang, C Ganesh, S Khazal, ... Blood, The Journal of the American Society of Hematology 139 (12), 1908-1919, 2022 | 48 | 2022 |
| Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide MR Gaballa, EC Besa Annals of hematology 93, 723-733, 2014 | 42 | 2014 |
| Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer AR Oran, CM Adams, X Zhang, VJ Gennaro, HK Pfeiffer, HS Mellert, ... Oncotarget 7 (45), 72395, 2016 | 36 | 2016 |
| Predictors of diabetic nephropathy MR Gaballa, YMK Farag Central European Journal of Medicine 8, 287-296, 2013 | 32 | 2013 |
| Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T‐cell therapy TM Dhawale, PC Johnson, MR Gaballa, AM Nelson, MW Lavoie, ... Cancer 129 (3), 441-449, 2023 | 12 | 2023 |
| Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia ML Alattar, M Ciccone, MR Gaballa, C Vitale, XC Badoux, G Manoukian, ... Leukemia & Lymphoma 56 (12), 3452-3454, 2015 | 12 | 2015 |
| KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma MR Gaballa, J Ma, M Rauf, R Bassett, O Pasvolsky, MR Tanner, Q Bashir, ... Bone marrow transplantation 57 (7), 1142-1149, 2022 | 10 | 2022 |
| Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance MR Gaballa, J Ma, MR Tanner, T Al-Juhaishi, Q Bashir, SA Srour, ... Leukemia & Lymphoma 63 (3), 710-721, 2022 | 9 | 2022 |
| Sleeping beauty generated CD19 CAR T-cell therapy for advanced B-cell hematological malignancies H Singh, SA Srour, DR Milton, J McCarty, C Dai, MR Gaballa, M Ammari, ... Frontiers in immunology 13, 1032397, 2022 | 8 | 2022 |
| Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4; 14): The MD Anderson Cancer Center Experience O Pasvolsky, MR Gaballa, DR Milton, A Masood, SS Sami, MR Tanner, ... Transplantation and cellular therapy 29 (4), 260. e1-260. e6, 2023 | 6 | 2023 |
| Cellular immunotherapy in lymphoma: beyond CART cells MR Gaballa, CA Ramos Current treatment options in oncology 21, 1-15, 2020 | 6 | 2020 |
| Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy PC Johnson, C Jacobson, A Yi, MR Gaballa, N Horick, DJ Rabideau, ... Journal for ImmunoTherapy of Cancer 10 (9), 2022 | 5 | 2022 |
| Acute lymphoblastic leukemia presenting initially as spinal cord compression: when chemotherapy alone is enough A Jang, KN Kram, SN Berger, MR Gaballa, LB Lu, DR Dunaway, ... Case Reports in Medicine 2020 (1), 8735724, 2020 | 5 | 2020 |
| Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the US Myeloma Immunotherapy Consortium A Afrough, H Hashmi, DK Hansen, S Sidana, C Ahn, LC Peres, D Dima, ... Blood Cancer Journal 14 (1), 63, 2024 | 4 | 2024 |
| Overview of Normal Hematopoiesis M Gaballa, CA Ramos Handbook of Benign Hematology 1, 1-22, 2019 | 3 | 2019 |
| Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients MJ Frigault, J Rosenblatt, B Dhakal, NS Raje, D Cook, M Gaballa, ... Blood 142, 1023, 2023 | 2 | 2023 |
| Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and/or refractory multiple myeloma M Frigault, J Rosenblatt, B Dhakal, N Raje, D Cook, MR Gaballa, ... Blood 140 (Supplement 1), 7439-7440, 2022 | 2 | 2022 |
| Handbook of Benign Hematology MP Mims, C Miller-Chism, IR Sosa Springer Publishing Company, 2019 | 2 | 2019 |
Youssef MK Farag, MD, PhD, MPHHarvard Medical School在 hms.harvard.edu 的电子邮件经过验证
